Clinical Trial Update: Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION) [Phase 2]

View source ↗

Summary

The Phase 2 ENVISION trial evaluating UBX1325 for neovascular age-related macular degeneration has completed, with safety, tolerability, and efficacy results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• UBX1325

Snippet

Sponsor: Unity Biotechnology, Inc. | Conditions: Neovascular Age-related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2024-08-07